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Abstract
Background: Fasciolosis remains a significant food-borne trematode disease causing high morbidity around the
world and affecting grazing animals and humans. A deeper understanding concerning the molecular mechanisms
by which Fasciola hepatica infection occurs, as well as the molecular basis involved in acquiring protection is
extremely important when designing and selecting new vaccine candidates. The present study provides a first
report of microarray-based technology for describing changes in the splenic gene expression profile for mice
immunised with a highly effective, protection-inducing, multi-epitope, subunit-based, chemically-synthesised
vaccine candidate against F. hepatica.
Methods: The mice were immunised with synthetic peptides containing B- and T-cell epitopes, which are derived
from F. hepatica cathepsin B and amoebapore proteins, as novel vaccine candidates against F. hepatica formulated
in an adjuvant adaptation vaccination system; they were experimentally challenged with F. hepatica metacercariae.
Spleen RNA from mice immunised with the highest protection-inducing synthetic peptides was isolated, amplified and
labelled using Affymetrix standardised protocols. Data was then background corrected, normalised and the expression
signal was calculated. The Ingenuity Pathway Analysis tool was then used for analysing differentially expressed gene
identifiers for annotating bio-functions and constructing and visualising molecular interaction networks.
Results: Mice immunised with a combination of three peptides containing T-cell epitopes induced high protection
against experimental challenge according to survival rates and hepatic damage scores. It also induced differential
expression of 820 genes, 168 genes being up-regulated and 652 genes being down-regulated, p value <0.05, fold
change ranging from −2.944 to 7.632. A functional study of these genes revealed changes in the pathways related to
nitric oxide and reactive oxygen species production, Interleukin-12 signalling and production in macrophages and
Interleukin-8 signalling with up-regulation of S100 calcium-binding protein A8, Matrix metallopeptidase 9 and CXC
chemokine receptor 2 genes.
Conclusion: The data obtained in the present study provided us with a more comprehensive overview concerning the
possible molecular pathways implied in inducing protection against F. hepatica in a murine model, which could be
useful for evaluating future vaccine candidates.
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Background
Fasciolosis is one of the most widespread food-borne
trematode diseases around the world, causing significant
economic losses in developing countries (estimated at
over 3 billion dollars per year) and affecting a wide range
of mammals, mainly ruminants [1, 2]. F. hepatica also
causes disease in human beings, most cases being
reported in Andean countries, Egypt and Iran [3–5].
Several reports have estimated that up to 17 million
people are infected and 91 to 170 million people live in
areas having a high risk of acquiring the disease [6].
Chronic F. hepatica infection causes hepatomegaly,
gallbladder and biliary duct thickening and dilatation,
leading to cholangitis, cholecystitis, usually accompanied
by obstruction of the biliary ducts. F. hepatica infection
also causes hepatic tissue damage and parenchymal de-
struction by juvenile fluke migration until the biliary
ducts are reached [7]. The immune response induced by
F. hepatica infection has been well described in experi-
mental models, typically being characterised by the pres-
ence of a dominant Th2 response with IL-4, IL-5 and
IL-13 secretion by spleen cells and regulatory cytokines
IL-10 and TGF-β by macrophages and dendritic cells
and Th1 immune response suppression in murine
models [8–10]. A dominant Th2 immune response also
occurs during the chronic phase of the disease in cattle,
involving high levels of IgG1 and little or no IgG2a; it
has also been shown that susceptibility to infection is cor-
related with the IgG1/IgG2a ratio, as well as IL-4/IFN-γ
levels [11–14]. Such immunomodulation/immunoregula-
tion of the host’s immune response by helminthic para-
sites is a key factor for successful infection and parasite
survival within host tissues. Besides the large body of
knowledge concerning an immune response in F. hepatica
infection, the precise molecular mechanisms leading to
protection are not yet well understood.
Fasciolosis control in animals and humans is currently
based on the mass administration of triclabendazole
which is active against both adult parasites located in
the bile ducts and immature flukes migrating through
the liver. This strategy has led to progressive drug-
resistance in animals [15–17]. Despite there is evidence
that a number of drugs have activity against F. hepatica,
it seems to be only partial, acting only either on the im-
mature or mature flukes. Also, the potential risk of sec-
ondary effects makes the replacement of triclabendazole
an ineffective strategy for its control [18–20]. Develop-
ing an effective vaccine represents one of the most ap-
pealing strategies for preventing this disease and
reducing the risk of infection in humans. No commercial
vaccines are yet available for F. hepatica although sig-
nificant progress has been made regarding attempts at
developing effective vaccines against infection caused
by other parasites, only a few vaccines have been
successfully tested against helminthic infection in ani-
mals [21–24]. Several antigens have been identified and
tested as vaccine candidates against F. hepatica infection.
Most studies have focused on using cathepsins, leucine-
aminopeptidase, haemoglobin, fatty-acid binding proteins
and glutathione S-transferase as vaccine candidates. Such
antigens have mainly been produced as recombinant pro-
teins and administered in different adjuvant-type formula-
tions. Vaccine efficacy has ranged from 13 to 97% in
cattle, measured as liver-fluke burden reduction [25, 26].
Subunit-based, chemically-synthesised vaccine candidates
represent a promising vaccine development strategy.
Using synthetic peptides offers a wide range of advantages:
inexpensive production, induction of a strong immune re-
sponse, avoid using living organisms thus minimising the
risk of acquiring disease, sequences which can interfere
with vaccination success become eliminated and peptides
from different antigens can be conjugated to the same
carrier [27, 28].
A previous study by our group involving the use of
bioinformatics tools showed the protection-inducing ability
of F. hepatica cathepsin B and amoebapore-derived B- and
T-cell epitopes which had been chemically-synthesised and
selected as vaccine candidates according to their induced
immune response in a murine model, reaching up to 66.7%
protection after immunisation [29]. According to the re-
sults obtained in the above mentioned article, where we
found reduction in hepatic damage and increase of survival
rates, in the present study we hypothesised that a combin-
ation of peptides with different induced-immune responses
could act in a synergic way in order to improve the immu-
noprotection in mice. In the present study we used the so-
called ADAD vaccination system. Previous reports by our
group have demonstrated the improvement in immuno-
protection trials against F. hepatica when using this vaccin-
ation system [30].
Better understanding concerning the molecular mech-
anisms by which F. hepatica infection occurs, as well as
the molecular basis involved in obtaining protection, is
extremely important in designing and selecting new
vaccine candidates. The present study involved using a
microarray-based methodology for studying the gene ex-
pression profile in the spleen of mice immunised with a
highly protective anti-F. hepatica vaccine candidate using
a combination of three synthetic peptides containing T-
cell epitopes, derived from F. hepatica cathepsin B and
amoebapore proteins, and the possible molecular path-
ways involved in inducing protection.
Methods
Ethical statement
Animal procedures complied with Spanish (Real Decreto
RD53/2013) and European Union (European Directive
2010/63/CE) guidelines regarding animal experimentation
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for the protection and humane use of laboratory animals.
The University of Salamanca’s accredited Animal Experi-
mentation Facilities (Registration number: PAE/SA/001)
were used for such procedures. The University of
Salamanca’s Ethics Committee also approved the pro-
cedures used in this study (Permit Number: 8402).
All efforts were made to minimise animal suffering.
Animals and parasites
Female, 6 week-old CD1 and BALB/c mice (Charles River
Laboratories, Barcelona, Spain) weighing 20 to 35 g were
used for the experiments. The animals were maintained in
the University of Salamanca’s animal care facility and kept
in plastic boxes with food and water ad libitum. The
animals were maintained with regular 12 h light–dark
periods at 20 °C. F. hepatica metacercariae were provided
by Ridgeway Research Ltd (Gloucestershire, UK) and
stored at 4 °C on 0.4% carboxymethylcellulose until use.
Metacercariae viability was confirmed by microscope
observation before infection.
In vivo protection studies: antigens, vaccine formulation
and immunisation trials
A previous study by our group led to identifying seven
F. hepatica cathepsin B and amoebapore-derived pep-
tides containing B- and T-cell epitopes as promising
vaccine candidates [29]. Briefly, from partial publically
available information in databases concerning F. hepatica
protein amino acid sequences, target-proteins were se-
lected in line with the following criteria: proteins having a
signal peptide sequence as predicted by SignalP 3.0 server,
freely available at http://www.cbs.dtu.dk/services/SignalP-
3.0/ [31] and proteins lacking a trans-membrane domain
as predicted by the TMHMM v2.0 server. Only proteins
having both a signal peptide and no trans-membrane do-
mains were selected and grouped into common families.
ClustalW was used for the multiple alignment of target
proteins’ amino acid sequences and only conserved or
semi-conserved regions were chosen for B- and T-cell epi-
tope prediction [32]. Subsequently, B- and T-cell epitopes
were chemically-synthesised and used for inoculating
BALB/c mice using an adjuvant adaptation (ADAD)
vaccination system [30]. Each peptide’s induced immune
response and protection-inducing ability was assessed in
in vivo studies. Seven peptides containing B- or T-cell
epitopes derived from F. hepatica cathepsin B and amoe-
bapore proteins were identified as promising vaccine
candidates.
Such single peptides were combined in the present
study, according to the induced immune response and
type of epitope. The amino acid sequence of each peptide
used here, as well as information concerning the protein it
came from is given (Additional file 1: Table S1A).
Forty-nine CD1 mice were divided into 7 groups (7 mice
each) as follows: group 1 consisted of untreated and unin-
fected controls, group 2 untreated and infected controls,
group 3 adjuvant-administered and infected controls,
group 4 those immunised with the combination of pep-
tides B6 and T14, group 5 mice immunised with peptides
B1, B5 and B6, group 6 mice immunised with peptides
T14, T15 and T16 and group 7 was immunised with
peptides containing B- and T-cell epitopes (B1, B2, B5,
B6, T14, T15 and T16). The mice were subcutaneously
immunised using an ADAD system [30]. Briefly, the
ADAD vaccination system included the vaccine antigen,
an immunomodulator (natural or chemically-synthesised),
together with non-haemolytic adjuvant Quillaja saponaria
saponins to form an emulsion with non-mineral oil in a
70/30 oil/water ratio. Vaccination with this system in-
cluded a set of 2 subcutaneous injections. The first (also
called adaptation) contained Q. saponaria and the immu-
nomodulator emulsified in non-mineral oil, but without
the vaccine antigen; the second injection was administered
5 days after adaptation and contained the vaccine antigen
with Q. saponaria and the immunodulator in the emul-
sion oil. Individual mouse immunisation involved
injecting doses formulated as follows: 100 μg chem-
ically synthesised aliphatic diamine immunomodulator
AA0029 [33] together with 20 μg Q. saponaria and,
when evaluated, 10 μg of each peptide. A final 100 μL/
injection volume was emulsified with non-mineral oil
(Montanide ISA763A, SEPPIC, Paris, France) in a 70/
30 oil/water ratio. Mice were immunised on day 0 and
two booster doses with 100 μL of the aforementioned
preparations were administered on days 14 and 28.
Experimental infection and protection assessment
Animals included in this study (except non-infected con-
trols – Group 1) were orally challenged with 7 F. hepatica
metacercariae 2 weeks after the last immunisation.
Humane endpoints were applied when an evidence of se-
vere pain, excessive distress, suffering or an impending
death was observable in any of the animals and then
euthanised with an intraperitoneal injection of 100 mg/kg
pentobarbital and necropsied to score hepatic damage.
Day 42 post-infection (p.i) was set as the trial’s end-point;
protected mice were considered to be animals remaining
alive until day 42 p.i. Mice still remaining alive were then
humanely euthanised and necropsied as above. Synthetic
peptides’ protection-inducing ability was then calculated
on the basis of survival rates, according to Kaplan Meier
estimators [34]. All animals were necropsied to score hep-
atic damage. Two experienced pathologists independently
evaluated liver lesions without knowing which group the
livers belonged to. Changes regarding size, colour and
consistency concerning blood vessels, bile ducts and sur-
face wounds were evaluated; a score was assigned to each
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feature: 0 points if no lesion was observed, 1 point if
a liver lobe was affected, 2 if an entire lobe was af-
fected and 3 if more than 1 lobe was affected. No le-
sion was assigned when the sum was 0 points, mild
(+) for 1–5 points, moderate (++) for 6–10 points
and severe (+++) for 11–14 points [35]. The infected
mouse survival rate percentage was then calculated as
the ratio of the number of surviving experimental
mice on day 42 p.i and the total of experimental mice
in each group.
Measuring antibody response
Sera from mice immunised with the aforementioned for-
mulations were analysed by ELISA for measuring total
IgG levels. The presence of specific antibodies raised
against F. hepatica was also detected in all the mice in-
fected with F. hepatica metacercariae according to the
methodology previously described [29].
Selecting the most protective antigen combination and
immunisation trial
Following in vivo protection studies in mice, the combin-
ation of peptides inducing the highest level of protection
was selected for gene expression profile analysis, taking
survival rates and hepatic damage score into account. Six
female BALB/c mice were included in this study and di-
vided into 2 groups (3 mice each) for the immunisation
trial. Mice in group 8 (n = 3) received no treatment
throughout (i.e. regarding their immunisation schedule).
Mice in group 9 (n = 3) were subcutaneously immunised
with 10 μg of antigen, 100 μg AA0029 and 20 μg Q. sapo-
naria emulsified with Montanide ISA763A on day 0. Two
booster doses with 100 μL of the aforementioned
preparations were injected on days 14 and 28. The
mice were humanely euthanised by intraperitoneal in-
jection of pentobarbital (100 mg/kg) two weeks after
the last immunisation and necropsied for spleen re-
covery and RNA isolation. Blood samples were also
taken prior to each vaccination dose and at the time of
necropsy.
Spleen RNA isolation
An RNeasy Mini Kit (Qiagen, Valencia, CA, USA) was
used for isolating total RNA from splenocytes from
both untreated and immunised mice, according to the
manufacturer’s instructions. A Nanodrop-1000 (Nanodrop
Technologies, Wilmington, USA) was used for measuring
the total amount of RNA and the Agilent 2100 Bioanaly-
zer platform was used for ascertaining quality. Only RNA
samples having an RNA integrity number (RIN) between
8 and 10 (on a 1 to 10 scale, 1 being the lowest quality
and 10 the highest) were used for the next procedures. Six
individual RNA samples were thus used for cDNA synthe-
sis and microarray analysis.
Microarray processing
A Mouse Gene 1.0 ST Affymetrix microarray was used
in this study. Labelling and microarray hybridisation
were carried out according to previously established
Affymetrix protocols. The approach involved synthesis-
ing first and second strand cDNA, double-stranded
cDNA purification, cRNA synthesis by in vitro tran-
scription, biotin-labelled cRNA recovery and quantita-
tion, cRNA fragmentation and subsequent hybridisation
to microarray slide and post-hybridisation washing. A
streptavidin-coupled fluorescent dye was used for detect-
ing hybridised cRNA. Briefly, 100–300 ng total RNA
was amplified and labelled using an Ambion WT ex-
pression kit (Ambion, Santa Clara, CA, USA) and then
hybridised to mouse gene 1.0 ST Array (Affymetrix).
The Affymetrix GeneChip system was used for washing
and scanning (GeneChip Hybridization Oven 640, Gen-
eChip Fluidics Station 450 and GeneChip Scanner 7G).
The 169-format GeneChip Mouse Gene 1.0 ST Array
contained around 25 probes designed along the full-
length of 28,853 well-annotated genes for mice. The
array was designed on the mouse genome sequence
(UCSC mm8, NCBI build 36) with comprehensive
coverage of RefSeq, putative complete CDS GenBank
transcripts, all Ensembl transcript classes and synteni-
cally mapped full-length human and rat mRNAs and
RefSeq NMs. The GeneChip Mouse Gene 1.0 ST Array
covers 100% of the NM sequences in the RefSeq data-
base (http://www.affymetrix.com/support/index.affx).
Microarray data analysis: normalisation, signal calculation,
differential expression and functional profiling
Cell intensity files (.CEL) were created using established
Affymetrix microarray analysis parameters. The robust
microarray analysis algorithm was used for background
correction, intra- and inter-microarray normalisation
and expression signal calculations [36–38]. Once the ab-
solute expression signal for each gene (i.e. the signal
value for each probe set) had been calculated in each
microarray, a method called significance analysis of
microarray was used for calculating significant differen-
tial expression and finding the gene probe sets charac-
terising highly metastatic samples [39]. This method
involves permutations providing robust statistical infer-
ence of the most significant genes and, by using a false
discovery rate (FDR), adjusting the raw p-values to take
multiple testing into account [40]. A <0.05 FDR cut-off
was used for all differential expression calculations. The
Ingenuity Pathway Analysis (IPA) tool (Ingenuity Sys-
tems, Mountain view, CA, USA) was used for identifying
the most significant biological mechanisms, pathways
and functional categories and also to construct and visu-
alise molecular interaction networks.
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PCR for experimental microarray validation
RNA from each biological sample was reserved for
carrying out a semi-quantitative reverse-transcription
PCR to validate a subset of the microarray data. Equal
amounts of total RNA from each experimental group
were pooled and reverse transcribed using a 1st strand
cDNA synthesis kit for reverse-transcription-PCR
(AMV) (Roche Applied Sciences, Indianapolis, IN,
USA), 20 μL final volume, according to the manufac-
turer’s instructions. The cDNA concentration obtained
was measured using a Nanodrop-1000 reader (Nanodrop
Technologies, Wilmington, DE, USA). Genes and
primers used for PCR (Additional file 1: Table S2B) were
representative of the transcripts which were significantly
up- or down-regulated during microarray analysis and de-
signed using Primer3 software, freely available at http://
bioinfo.ut.ee/primer3-0.4.0/. Primers were designed to be
specific for each up- and down-regulated gene so selected
and ensure that PCR products would be 140–280 bp.
Twenty-five PCR amplification cycles were performed
on a Mastercycler gradient (Eppendorf ) thermocycler,
as follows: denaturing at 94 °C for 30 s, annealing at
55 °C for 30 s (depending on Tm for each primer) and a
final extension step at 72 °C for 5 min. PCR products were
visualised on 2.0% (wt/vol) agarose gels with ethidium
bromide. Genomic DNA contamination was ruled out for
each RNA sample. Free ImageJ software (https://imagej.
nih.gov/ij/) [41] was used for the quantitative digital ana-
lysis of the image data from electrophoresis gels.
Statistical analysis
The results were expressed as the mean and standard
error of the mean. Normal data distribution was checked
using a non-parametric Kolmogorov-Smirnov test. Dif-
ferences between groups were found using a one-way
ANOVA test and Tukey’s honest significance test or the
Kruskal Wallis test. Statistical analysis was considered
significant at p < 0.05. SPSS 21.0 was used for graphical
representation. The R statistical software was used for
bioinformatics analysis, using Bioconductor [42] and
GATExplorer [43] custom packages. Kaplan-Meier sur-
vival curves were used for evaluating survival rates.
Results
Immunisation and experimental infection
An ELISA assay was performed during two stages of our
experimental procedure to assess the success of the im-
munisation trial and infection. Each group of mice
immunised with any of the synthetic-peptide combina-
tions induced levels of IgG. It was observed that the
highest levels of IgG were induced in the group of mice
immunised with the synthetic peptides containing B-cell
epitopes. High levels of IgG raised against the excretory/
secretory antigen from F. hepatica in orally infected
mice were also detected. No IgG levels were detected in
any of mice belonging to the non-immunised-uninfected
control group (Group 1) (Additional file 2: Figure S1).
In vivo protection studies: measuring the survival rates
Immunising mice with any combination of synthetic
peptides led to enhancing their survival rates compared to
the non-immunised and infected control group. Mice from
the non-immunised and infected control group died
between days 24 and 34 p. i. Taking this issue into account,
protected mice were considered to be animals remaining
alive until day 42 p.i; on the contrary, non-protected mice
were considered animals which died before day 42 p.i.
Figure 1a shows that immunising mice with any combin-
ation of the synthetic peptides containing either B- or T-
cell epitopes induced some degree of protection against
experimental infection with F. hepatica metacercariae.
A 71.4% (5 of 7 mice alive) survival rate was obtained
in the group of mice immunised with the combination
of peptides containing T-cell epitopes (T14, T15 and
T16; Group 6), thus representing the highest survival
rate obtained in the present study (Fig. 1a). All mice
from group g4 (immunised with peptides B6 + T14), g5
(immunised with peptides B1 + B5 + B6) and g7 (immu-
nised with peptides B1 + B2 + B5 + B6 + T14 + T15 + T16)
achieved a 57.1% survival rate (4 of 7 mice alive). How-
ever, protection-inducing ability was ranked as follows:
(B1 + B5 + B6; Group 5) > (B6 + T14; Group 4) > (B1 +
B2 + B5 + B6 + T14 + T15 + T16; Group 7), taking the
time of each animal’s death into account in the experi-
mental groups (Fig. 1a). Mice died in the following days:
group 2 on days 24 (1 mouse), 27 (2 mice), 28 (3 mice)
and 34 (1 mouse); group 3 on days 27, 29, 31 and 34 (1
mouse each day); group 4 on days 27, 29 and 33 (1 mouse
each day); group 5 on days 26, 28 and 36 (1 mouse each
day); group 6 on days 28 and 34 (1 mouse each day) and
group 7 on days 25 (1 mouse) and 27 (2 mice).
Hepatic lesion scores
Forty-two days after experimental infection, all surviving
mice were humanely euthanised and necropsied for
evaluating hepatic lesions. This revealed that protected
mice had lower hepatic damage scores than non-
protected mice ([6.3 ± 0.5] cf [12.2 ± 0.4]) (p < 0.05). Mice
having minor lesions were also classified (0 to 5 score),
as were moderate lesions (6 to 10 score) and severe le-
sions (11 to 14 score). Non-protected mice only had
moderate (30%) or severe lesions (70%) whilst protected-
mice mainly had minor (48%) or moderate lesions (38%),
thereby indicating a correlation between protection and
hepatic damage score.
The group of mice immunised with the combination
of peptides having T-cell epitopes (group 6) had the
lowest hepatic damage score compared to the infected
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group ([6.6 ± 0.6] cf [12.0 ± 1.5]) (p < 0.05); a 45% reduc-
tion was observed in this group, again showing these
peptides’ effectiveness as anti-F. hepatica infection vac-
cine candidates. Mice immunised with the full combin-
ation of peptides containing B- and T-cell epitopes
(group 7) also had significantly reduced hepatic damage
([7.3 ± 1.3] cf [12.0 ± 1.5]) (p < 0.05), reaching 39% re-
duction compared to the untreated and infected control
group. Table 1 gives the hepatic damage score for each
group immunised with any combination of peptides
used in the present study. There was some reduction, non
significant (22%) ([9.3 ± 1.8] cf [12.0 ± 1.5]) (p > 0.05) re-
garding liver damage in the group 3 (mice immunised
with ADAD components). A representative image of
macroscopic lesion in the liver of mice infected (group 1)
and mice immunised with the combination of synthetic
peptides containing T-cell epitopes (group 6) is shown
(Fig. 1b).
The establishment of criteria for protection due to F.
hepatica infection is well defined in natural infection
hosts such as cows, lambs, goats and sheep. However,
when using mouse as experimental model such criteria
become unsuitable, mainly due to the very reduced
worm recovered in the liver, hampering any statistical
support. Thus, in the present study we did not take into
account the number of worms recovered in the liver as a
criterion for protection.
Selecting the most protective antigen combination,
immunisation trial and spleen RNA isolation
Following in vivo protection studies, the combination of
peptides containing T-cell epitopes as the most promising
vaccine candidate against F. hepatica infection was se-
lected for the gene expression profile studies. Two-weeks
after the last immunisation, the spleens from each mouse
(6 in total) were aseptically removed and RNA was iso-
lated. An Agilent 2100 Bioanalyzer was then used for
assessing RNA integrity and purity. All RNA-isolated sam-
ples had an RNA integrity number of 10 (on a 1 to 10
scale, 1 being the lowest quality and 10 the highest), thus
indicating an optimal starting product for cDNA synthesis
and microarray design (Additional file 3: Figure S2).
Microarray analysis and data pre-processing
The data discussed in this publication have been deposited
in NCBI’s Gene Expression Omnibus [44] and is accessible
through GEO Series accession number GSE69611 (https://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69611).
The gene expression profile in the spleen of mice
Table 1 Assessing macroscopic hepatic lesions in CD1 mice




2 Infected 12.0 ± 1.5
3 Adjuvant treated 9.3 ± 1.8 22
4 B6 + T14 8.3 ± 1.8 31
5 B1 + B5 + B6 10.3 ± 1.6 14
6 T14 + T15 + T16 6.6 ± 0.6 45*
7 B1 + B2 + B5 + B6 +
T14 + T15 + T16
7.3 ± 1.3 39*
The mice were immunised with combinations of synthetic peptides containing
B- and T-cell epitopes using the ADAD vaccination system which had been
orally challenged with 7 F. hepatica metacercariae
*p < 0.05 compared to infected controls
a b
Fig. 1 Immunoprotection in mice immunised with the synthetic peptides. a Kaplan-Meier curves depicting survival rates in mice immunised with
any combination of peptides containing B- and T-cell epitopes as vaccine candidates which had also been orally infected with F. hepatica metacercariae.
The survival rates of mice from both untreated and infected controls are also represented. The humane endpoint was established when an indicator of
severe pain, excessive distress, suffering or an impending death was observed in any animal which was then euthanised with an intraperitoneal injection
of pentobarbital at 100 mg/kg using 30 g needles. b Representative macroscopic lesion in infected mice (group 1, upper part) compared to
mice immunised with a combination of peptides containing T-cell epitopes (T14 + T15 + T16; group 6, lower part)
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immunised with the combination of synthetic peptides con-
taining T-cell epitopes (T14, T15 and T16) formulated in
ADAD (Group 9) was studied as it had the highest immu-
noprotection rates in mice experimentally challenged with
F. hepatica metacercariae compared to untreated mice
(group 8), thereby providing insights into the potential
pathways involved in inducing protection.
Raw data was quality assessed to ensure its integrity
before any analysis was performed. Microarray data was
background corrected by using the robust microarray
analysis algorithm to eliminate background noise. A box
plot showing the normalised unscaled standard error
for each microarray is depicted (Additional file 4:
Figure S3). Normalisation of data and subsequent dif-
ferential expression signal calculation led to identifying
820 genes being differentially expressed (p < 0.05) as a
result of immunisation with our vaccine candidate
(peptides containing T-cell epitopes derived from F.
hepatica cathepsin B and amoebapore proteins; com-
parison between groups 8 and 9). Signal intensity calcu-
lation for differentially expressed genes (fold change)
from both down- and up-regulated genes ranged from
−2.944 to 7.632. Additional file 5: Table S2, gives the
complete list and provides additional information re-
garding each gene being differentially expressed. Immu-
nising mice with our vaccine candidate led to the
differential expression of 820 genes; 652 genes were
down-regulated and 168 up-regulated. However, only
12 down-regulated genes (1.8%) had a fold change value
lower than −2, whilst 37 up-regulated genes (22.0%)
had a fold change value higher than 2.
Pathway analysis
The free version of the IPA tool was used for data inter-
pretation and comparing the non-immunised control
group (group 8) to the group immunised with our vac-
cine candidate (group 9); 121 canonical pathways were
identified having a p-value <0.05, 37 of them being asso-
ciated with an immune response. Figure 2 shows the
most representative immune response-associated path-
ways: CD28 signalling in T-helper cells, iCOS – iCOS
signalling in T-helper cells, PKC signalling in T-
lymphocytes, IL-12 signalling and production in macro-
phages and the production of nitric oxide and reactive
oxygen species were the most significant pathways
undergoing changes during our immunisation procedure.
Strong down-regulation occurred with 391 (95.6%) genes
being down-regulated but only 18 (4.4%) being up-
regulated. Table 2 lists the genes having the highest
differential expression and their participation in each
canonical immune response associated pathway. Addi-
tional file 5: Table S3, provides a detailed list including
all the signalling pathways and their associated-genes
being differentially expressed by immunisation.
Biological processes
The differentially expressed genes were also analysed to
identify changes in the biological process associated with
Fig. 2 Ingenuity Pathway Analysis (IPA) showing the most representative canonical pathways associated with immune responses in the spleen of
mice immunised with a combination of peptides containing T-cell epitopes (T14, T15 and T16). The figure shows the number of genes being
differentially expressed compared to the untreated control group. Red represents the number of up-regulated genes whilst green represents
down-regulated ones
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Table 2 Genes having the highest differential expression associated with immune response-related pathways
Gene symbol Description p-value Fold change Associated pathway
S100A8 S100 calcium binding protein A8 1.62E-03 5.934 IL12 signalling and production in macrophages
Production of nitric oxide and reactive oxygen species
MMP9 Matrix metallopeptidase 9 3.07E-03 4.501 IL8 signalling
Leukocyte extravasation signalling
CXCR2 Chemokine (C-X-C motif) receptor 2 3.39E-04 3.401 IL8 signalling
IFITM1 Interferon induced transmembrane protein 1 2.13E-03 2.375 IFN signalling
CCR3 Chemokine (C-C motif) receptor 3 Gene 1.31E-03 1.655 CCR3 signalling in eosinophils
Chemokine signalling
ACTA2 Actin, alpha 2, smooth muscle, aorta 1.77E-03 1.640 Crosstalk between DC and NK cells
Leukocyte extravasation signalling
Integrin signalling
TAB1 Mitogen-activated protein kinase 7 interacting
protein 1




CD40LG CD40 ligand 1.41E-03 −1.740 T helper cell differentiation
CD40 signalling
IL12 signalling and production in macrophages
NF-kB signalling
JUN Jun oncogene 4.08E-03 −1.587 CD28 signalling in T helper cells
IL12 signalling and production in macrophages





PLCG1 phospholipase C, gamma 1 5.33E-03 −1.541 iCOS-iCOSL signalling in T-helper cells
PCK signalling in T-lymphocytes
Production of nitric oxide and reactive oxygen species
Phospholipase C signalling
IL15 signalling
PRKCQ protein kinase C, theta 3.14E-03 −1.461 T-cell receptor signalling
CCR5 signalling in macrophages
Natural killer cells signalling
Apoptosis signalling
B-cell receptor signalling
PRKD3 protein kinase D3 6.26E-03 −1.440 Calcium-induced T-lymphocyte apoptosis
LPS stimulated MAPK signalling
CCR5 signalling in macrophages
CCR3 signalling in eosinophils
CXCR4 signalling
The genes analysed here were used when comparing non-immunised mice to mice immunised with a combination of T-cell-epitope-containing
peptides (T14 + T15 + T16)
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the immune response, taking the amount of genes being
differentially expressed into account (p < 0.05) and each
biological process’ statistical significance, regardless the
fold change value. Figure 3 shows that the most signifi-
cant biological processes changed by immunisation with
our vaccine candidate were related to the induced- im-
mune response. The top three functions associated with an
immune response were immunological disease (including
up-regulation of C3, MMP9, BRCA2, CCRR, CXCR2,
ALOX5), cell-to-cell signalling and interaction (including
up-regulation of ANXA1, C3, CLIC4, S100A9, ELANE)
and inflammatory response (including up-regulation of
FPR1, C1QA, C5AR1, CD200R1, LTBR).
It is worth stressing that down-regulation was ob-
served in most differentially expressed genes (134);
however, the fold change values were higher in the up-
regulated genes. Differential expression of the most
significant genes was ranked as follows: C3 > ANXA1 >
CXCR2 > LTBR >MMP9 > ALOX5 > C5AR1 > S100A9 >
ELANE > CCR3. Figure 4 shows their participation in
different biological functions, whilst a detailed list of all
differentially expressed genes and their participation
in functions and associated-functions is given (Addi-
tional file 5: Table S4). Our approach focused on genes
being up-regulated and their canonical pathways as
our goal was to find a link between an immune re-
sponse induced upon vaccination and the protective
efficacy so achieved; however, it is worth mentioning
that most genes being differentially expressed be-
longed to the down-regulated group and affected a
wide range of canonical and signalling pathways.
CD28 signalling and iCOS-iCOSL in T-helper cells
and T-cell receptor signalling were the most representative
canonical pathways being down-regulated. Concerning
genes, CD40LG, JUN1, PLCG1 and IKBKE had the highest
down-regulation in the aforementioned pathways.
PCR for microarray validation
Semi-quantitative reverse-transcription PCR was used in
the present study for validating differentially expressed
genes, using free ImageJ software [41] for calculating
each band’s intensity; six genes were randomly selected
for such confirmation.
The PCR expression patterns agreed with those ob-
tained in the microarrays. Figure 5 shows that all genes
being up-regulated had higher band intensity in the
group of mice immunised with the vaccine candidate
compared to the untreated group, whereas down-
regulated genes had lower band intensity in the immu-
nised group. Fold change was calculated by measuring
each band’s intensity: CXCR2 2.70, IFITM1 1.40, S100A8
1.23, CD40LG -1.86, IKBKB -1.57 and PLCG1 -1.18.
Discussion
The present work involved using a microarray-based
technology together with protection studies against F.
hepatica to better understand the gene expression pro-
file and immunological mechanisms leading to protec-
tion in mice immunised with a novel anti-F. hepatica
vaccine candidate.
F. hepatica cathepsin B and amoebapore-like proteins
were selected as vaccine candidates in the present study.
According to the pertinent literature, it is well known
that F. hepatica cathepsins are secreted proteins which
are differentially expressed during the life stages of
flukes; they have different associated functions in each
stage and are also considered significant vaccine can-
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Fig. 3 The biological process involved in spleen differentially expressed genes compared to the non-immunised control group. a The total number of
genes is showed in parentheses and the significance of each biological process is indicated by its p value. b The amount of both up- and
down- differentially expressed genes is indicated for each biological process. Red represents the amount of up-regulated genes whilst green
represents down-regulated ones
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metacercariae and newly excysted juveniles whilst
cathepsin L is mainly expressed in newly excysted ju-
veniles and adult worms [45]. F. hepatica cathepsins
are considered important vaccine candidates; several
studies have demonstrated their protection-inducing
ability in different experimental models [46–49]. F.
hepatica amoebapore proteins have shown amino acid
sequence similarity with saposin-like proteins. These
proteins have been shown to be highly immunogenic
and their inducing-protection ability has also been
demonstrated in mice and rabbits. Concerning F. hepatica
saposin-like protein expression, up-regulation has been
demonstrated in eggs, newly excysted juveniles and adults
and down-regulation in miracidia [50]. The recently pub-
lished draft genome for F. hepatica identified three proteins
from amoebapore-like proteins referred to as saposin-like
proteins. The gene expression profile has revealed up-
regulation of the amoebapore-like protein (putative,
uncharacterised; Uniprot blast hits Q4KSL8; Q24939;
Q24938; Q9NAT2; B6ZBP3) in newly excysted juveniles,
juvenile (21 days) and adult stages. The amoebapore-like
protein (Uniprot blast hits Q9NAT2; B6ZBP3) is down-
regulated in the newly excysted juveniles stage but up-
regulated in the juvenile (21 days) and adult stages. The
third amoebapore-like protein (Uniprot blast hits Q9NAT2;
B6ZBP3; Q4KSL7; Q4KSL8; Q24939) is also down-
regulated in newly excysted juveniles stages but highly up-
regulated in the juvenile (21 days) and adult stages [51].
To date, little is known concerning the development
of subunit-based, chemically synthesised anti-F. hepatica
vaccines [52, 53]. The present study involved selecting
mouse survival rates (represented by Kaplan-Meier
survival curves) and hepatic damage score as indicators
for protection. Recovered worm count should also be in-
cluded as protection indicator in an ideal scenario; how-
ever, the number of worms recovered per animal was
too low when using the mouse model of infection for F.
hepatica experiments; drawing conclusions for protec-
tion based on worm count could thus be biased. It was
also considered that worm count in infected mice was
indeed a less reliable method for assessing protection.
Mice immunised with a combination of synthetic peptides
containing either B- or T-cellepitopes increased mouse
survival rate in the present study. Despite the peptides
IL-12 signaling and production in macrophages 2.699
Production of nitric oxide and reactive oxygen species 2.667
iNOS signaling 2.431
Lymphotoxin B receptor signaling 2.16
Crosstalk between dendritic cells and NK cells 1.948
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Fig. 4 The most representative signalling pathways and their associated up- and down-regulated genes are represented. The fold change of each
gene is shown in parenthesis. The significance (−log p value) of each signalling pathway is also indicated by the scale to the right of the graph.
Signalling pathway analysis was done only in the group of mice immunised with the combination of peptides containing T-cell epitopes (T14, T15, T16).
Red and green squares represent genes belonging to each signalling pathway, whereas gray squares indicate absence of those genes in that pathway
a
b
Fig. 5 The microarrays were validated by using PCR reactions. Panel
a depicts up-regulated genes and panel b down-regulated genes.
Lane 1 represents the corresponding PCR amplification of the indicated
gene from untreated mice and lane 2 represents the corresponding PCR
amplification of the indicated gene from the immunised mouse group.
Each mouse’s RNA was pooled and used for RT-PCR and the genes for
validation were randomly assigned. The results are representative
of three individual experiments. MWM: Molecular Weight Marker
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tested were originally designed based on their good
predicted binding to the H2-Ed MHC type displayed
by the syngeneic BALB/c mice as a model to obtain a
specific response against F. hepatica, testing the
protective immune response induced in an outbred
model such as CD1 mice could represent better the
variability observed in the target population for
vaccination such as sheep and cattle.
The combination of peptides containing T-epitopes
(T14 + T15 + T16; group 6) induced the highest survival
rate, thereby supporting our hypothesis that a multi-
epitope-based vaccine is necessary for obtaining higher
immune-protective responses against helminthic infec-
tion. A previous study by our group demonstrated the
immunoprotective efficacy of single peptides containing
B- or T-cell epitopes against experimental infection with
F. hepatica metacercariae, reaching good immunopro-
tective levels with the so-called peptide T15 [29]. Here,
we have demonstrated that adding peptides T14 and
T16 induced better protective levels than the single pep-
tide T15, taking the Kaplan-Meier survival curves and
hepatic damage into account.
Adding peptides containing B-cell epitopes to our vac-
cine candidate induced a loss of immunogenicity as mea-
sured by determining IgG levels and immunoprotection
levels became reduced. It is worth noting that vaccinating
mice with ADAD vaccination system components induced
little protection, as indicated by Kaplan-Meier survival
curves, and little reduction was observed regarding
hepatic damage.
A microarray-based methodology was used to identify
the gene expression profile in BALB/c mice immunised
with our most protective antigen combination formu-
lated in ADAD vaccination system (Qs + AA0029 +
T14 + T15 + T16) and the uninfected control mice to
gain fresh insight into the molecular and immuno-
logical basis leading to protection. Eosinophilia has
been associated with helminth infection, although its
precise role in conferring protection is still controver-
sial and several studies have been concerned with the
role of eosinophils in protection by using both in vitro
and in vivo studies [54–56]. CCR3 is a receptor for C-C
type chemokines, including eotaxin, MCP-3, MCP-4
and RANTES, and is highly expressed in eosinophils.
Our study found up-regulation of the CCR3 chemokine
receptor in mice immunised with our vaccine candi-
date, thus supporting the hypothesis that eosinophils
could be mediating mechanisms leading to protection
in F. hepatica infection. By contrast, other studies have
shown that eosinophils suffer induced-apoptosis by ex-
cretory/secretory products from F. hepatica, thus sug-
gesting that proposing a role for such cells in inducing
protection should be taken with caution [57]. IL-8 re-
ceptor gene (CXCR2) up-regulation was also found.
CXCR2 is mainly expressed on neutrophil surface,
providing some information concerning the possible
mechanisms involved in Th2 cell-mediated immune
clearance pathways. Up-regulation of other types of C-
X-C family chemokines (i.e. CXCR4) has been shown to
be essential in animals which are genetically-resistant
to nematode parasites [58].
Up-regulation of the endogenous toll-like receptor-4
agonist was also achieved by the immunisation trial
through expression of the S100A8/S100A9 complex,
known as calprotectin. These two members of the
damage associated molecular pattern family are secreted
during phagocyte stress response [59]. Evidence has been
presented regarding neutrophil and S100A8 neutrophil
chemokine localisation in fibrotic areas in a murine
model of Schistosoma japonicum, suggesting its implica-
tion in the induction of fibrosis [60]. S100A8 and
S100A9 are up-regulated in liver and spleen during S.
japonicum infection. It has also been suggested that
S100A8 up-regulation may protect against oxidative
tissue damage. There is no evidence to date regarding
the precise role of the S100A8/S100A9 complex con-
cerning F. hepatica infection or acquiring protective im-
munity. The present study’s results suggested activation
by innate immunity with up-regulation of both S100A8
and S100A9 in the spleen of mice immunised with our
vaccine candidate, a key factor in inducing protective
immunity, at least in a murine model.
Reports in the pertinent literature have investigated
the role of C3 during schistosome infection in a murine
model. C3 depletion has led to a significant reduction in
Th2-associated cytokines without any correlation with
worm development or liver pathology. C3-defficient
mice have not been able to effectively clear adult worms
after treatment with praziquantel [61]. C3 depletion
seems to be agree as complement activation do not
represent an immunologic mechanism leading to immu-
noprotection against F. hepatica infection. Also, nitric
oxide is related to Th1 immune response with subse-
quent macrophage activation, unleashing nitric oxide
liberation as an immunoprotector-associated mechanism.
However, we could not provide any experimental evidence
showing its correlation with hepatic damage or fluke
burden reduction.
It has also been shown that nitric oxide production is
enhanced by the synergic effect of both IL-12 and IL-8.
IL-12 is considered to be a cytokine inducing a Th1 im-
mune response, with IFN-γ overproduction. IL-12 plays
a key role in helminthic infection by inhibiting Th2
immune responses which are essential for a parasite sur-
viving inside a mammalian host [62]. It was observed in
our study that the IL-12 signalling pathway was signifi-
cantly altered by the immunisation trial, being the genes
S100A8, CD40LG and JUN differentially expressed,
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making it a key factor leading to protection. Significant
alteration in IL-8 signalling was observed after mice
were immunised with our vaccine candidate, involving
up-regulation of receptors for IL-8, MMP9 and CXCR2.
Nitric oxide production has been studied in vitro in in-
fection caused by helminths involving Trichinella spp,
Dirofilaria immitis and Ascaris suum antigens; a correl-
ation has been found between antigen-dependent stimu-
lation and nitric oxide levels [63–65]. Nitric oxide could
regulate inflammation produced by egg release, prevent
hepatic cell damage, the spread of damage in the liver
and reduce granuloma formation by S. mansoni [66].
Concerning F. hepatica infection, nitric oxide produc-
tion has been studied in infected rats, showing reduced
nitric oxide levels 7 and 14 days p.i. Such reduction has
been associated with excretory/secretory released anti-
gens, constituting one of the defence mechanisms used
by this parasite during its migration through the peritoneal
cavity of a mammalian host [67]. It could be hypothesised
that changes in nitric oxide signalling pathway induced by
the immunisation trial could have been involved in indu-
cing protective immunity, thereby becoming a necessary
condition for such immunoprotection. No previous reports
are available concerning the expression levels of MMP9
during F. hepatica infection. In S. mansoni-infected mice
there is evidence of changes in MMP gene family expres-
sion in the chronic phase of the disease, which is associated
to degradation of collagen deposited in tissues. Up regula-
tion of MMP2, MMP3 and MMP8 has been reported in S.
mansoni-infected mice but no significant differential
expression was observed in MMP9 gene [68]. S. mansoni-
infected patients have had low CXCR1 and CXCR2 fre-
quency during the acute phase of the disease but high IL-8
levels in sera [69]. Besides high CXCR1 and CXCR2 ex-
pression in our study, we could not provide any evidence
of IL-8 in conferring protective immunity; however, it
provided a first insight concerning its implication in F.
hepatica protection-inducing mechanisms.
Conclusions
The present study’s findings have highlighted the immu-
noprophylactic potential of T-cell-epitope-containing syn-
thetic peptides when used in combination and formulated
in the ADAD vaccination system, thus supporting the idea
that developing multi-epitope, subunit-based and
chemically-synthesised vaccines produces better results
than immunisation with single antigens. We have also re-
ported for the first time a transcriptional profile concern-
ing the splenocytes of mice immunised with a promising
anti-F. hepatica vaccine candidate. The results showed
that many molecular mechanisms and signalling pathway
alterations are potentially involved in conferring protective
immunity, at least in a murine model. We have
highlighted the potential involvement of genes and
signalling pathways associated with nitric oxide produc-
tion, IL-12 signalling and IL-8 signalling in conferring pro-
tective immunity. This study has provided us with insights
regarding possible cellular and molecular mechanisms in-
volved in protection against F. hepatica; however further
studies are necessary for experimentally confirming our
hypothesis.
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